e10vq
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTER ENDED JUNE 30, 2006
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
|
|
|
INDIANA
(State or other jurisdiction of
incorporation or organization)
|
|
35-0470950
(I.R.S. Employer
Identification No.) |
LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285
(Address of principal executive offices)
Registrants telephone number, including area code (317) 276-2000
Indicate by check mark whether the Registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months and (2) has been subject to such filing requirements for the
past 90 days.
Yes þ No o
Indicate by check mark whether the Registrant is a large accelerated filer, an
accelerated filer or a non-accelerated filer.
Large accelerated filer þ Accelerated filer o Non-accelerated filer o
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).
Yes o No þ
The number of shares of common stock outstanding as of July 20, 2006:
|
|
|
Class |
|
Number of Shares Outstanding |
Common
|
|
1,130,398,796 |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(Unaudited)
Eli Lilly and Company and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions, except per-share data) |
Net sales |
|
$ |
3,866.9 |
|
|
$ |
3,667.7 |
|
|
$ |
7,581.6 |
|
|
$ |
7,165.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
860.6 |
|
|
|
871.3 |
|
|
|
1,667.1 |
|
|
|
1,730.3 |
|
Research and development |
|
|
774.8 |
|
|
|
762.4 |
|
|
|
1,515.6 |
|
|
|
1,464.6 |
|
Marketing and administrative |
|
|
1,237.9 |
|
|
|
1,146.1 |
|
|
|
2,380.8 |
|
|
|
2,236.5 |
|
Asset impairments, restructuring, and other special charges |
|
|
|
|
|
|
1,073.4 |
|
|
|
|
|
|
|
1,073.4 |
|
Other income net |
|
|
(46.9 |
) |
|
|
(45.4 |
) |
|
|
(79.1 |
) |
|
|
(144.0 |
) |
|
|
|
|
|
|
2,826.4 |
|
|
|
3,807.8 |
|
|
|
5,484.4 |
|
|
|
6,360.8 |
|
|
|
|
Income (loss) before income taxes |
|
|
1,040.5 |
|
|
|
(140.1 |
) |
|
|
2,097.2 |
|
|
|
804.3 |
|
Income taxes |
|
|
218.5 |
|
|
|
111.9 |
|
|
|
440.4 |
|
|
|
319.7 |
|
|
|
|
Net income (loss) |
|
$ |
822.0 |
|
|
$ |
(252.0 |
) |
|
$ |
1,656.8 |
|
|
$ |
484.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share basic |
|
$ |
.76 |
|
|
$ |
(.23 |
) |
|
$ |
1.53 |
|
|
$ |
.45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share diluted |
|
$ |
.76 |
|
|
$ |
(.23 |
) |
|
$ |
1.53 |
|
|
$ |
.44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid per share |
|
$ |
.40 |
|
|
$ |
.38 |
|
|
$ |
.80 |
|
|
$ |
.76 |
|
|
|
|
See Notes to Consolidated Condensed Financial Statements.
2
CONSOLIDATED CONDENSED BALANCE SHEETS
Eli Lilly and Company and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
2,669.7 |
|
|
$ |
3,006.7 |
|
Short-term investments |
|
|
1,921.0 |
|
|
|
2,031.0 |
|
Accounts receivable, net of allowances
of $64.9 (2006) and $66.3 (2005) |
|
|
2,101.8 |
|
|
|
2,313.3 |
|
Other receivables |
|
|
415.0 |
|
|
|
448.4 |
|
Inventories |
|
|
2,099.2 |
|
|
|
1,878.0 |
|
Deferred income taxes |
|
|
648.9 |
|
|
|
756.4 |
|
Prepaid expenses |
|
|
733.0 |
|
|
|
362.0 |
|
|
|
|
TOTAL CURRENT ASSETS |
|
|
10,588.6 |
|
|
|
10,795.8 |
|
|
OTHER ASSETS |
|
|
|
|
|
|
|
|
Prepaid pension |
|
|
2,360.8 |
|
|
|
2,419.6 |
|
Investments |
|
|
1,287.8 |
|
|
|
1,296.6 |
|
Sundry |
|
|
2,110.4 |
|
|
|
2,156.3 |
|
|
|
|
|
|
|
5,759.0 |
|
|
|
5,872.5 |
|
PROPERTY AND EQUIPMENT |
|
|
|
|
|
|
|
|
Land, buildings, equipment, and construction-in-progress |
|
|
13,568.1 |
|
|
|
13,136.0 |
|
Less allowances for depreciation |
|
|
(5,480.1 |
) |
|
|
(5,223.5 |
) |
|
|
|
|
|
|
8,088.0 |
|
|
|
7,912.5 |
|
|
|
|
|
|
$ |
24,435.6 |
|
|
$ |
24,580.8 |
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Short-term borrowings |
|
$ |
738.6 |
|
|
$ |
734.7 |
|
Accounts payable |
|
|
648.9 |
|
|
|
781.3 |
|
Employee compensation |
|
|
374.1 |
|
|
|
548.8 |
|
Dividends payable |
|
|
438.3 |
|
|
|
436.5 |
|
Income taxes payable |
|
|
700.9 |
|
|
|
884.9 |
|
Other current liabilities |
|
|
1,744.5 |
|
|
|
2,330.1 |
|
|
|
|
TOTAL CURRENT LIABILITIES |
|
|
4,645.3 |
|
|
|
5,716.3 |
|
|
LONG-TERM DEBT |
|
|
5,578.0 |
|
|
|
5,763.5 |
|
DEFERRED INCOME TAXES |
|
|
759.4 |
|
|
|
695.1 |
|
OTHER NONCURRENT LIABILITIES |
|
|
1,524.4 |
|
|
|
1,614.0 |
|
|
SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Common stock |
|
|
707.0 |
|
|
|
706.9 |
|
Additional paid-in capital |
|
|
3,365.2 |
|
|
|
3,323.8 |
|
Retained earnings |
|
|
10,817.6 |
|
|
|
10,027.2 |
|
Employee benefit trust |
|
|
(2,635.0 |
) |
|
|
(2,635.0 |
) |
Deferred costs-ESOP |
|
|
(103.7 |
) |
|
|
(106.3 |
) |
Accumulated other comprehensive loss |
|
|
(120.0 |
) |
|
|
(420.6 |
) |
|
|
|
|
|
|
12,031.1 |
|
|
|
10,896.0 |
|
Less cost of common stock in treasury |
|
|
102.6 |
|
|
|
104.1 |
|
|
|
|
|
|
|
11,928.5 |
|
|
|
10,791.9 |
|
|
|
|
|
|
$ |
24,435.6 |
|
|
$ |
24,580.8 |
|
|
|
|
See Notes to Consolidated Condensed Financial Statements.
3
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Eli Lilly and Company and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,656.8 |
|
|
$ |
484.6 |
|
Adjustments to reconcile net income to cash flows from
operating activities: |
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities |
|
|
(1,357.3 |
) |
|
|
(369.0 |
) |
Depreciation and amortization |
|
|
414.0 |
|
|
|
317.4 |
|
Stock-based compensation expense |
|
|
191.3 |
|
|
|
208.2 |
|
Change in deferred taxes |
|
|
120.7 |
|
|
|
(175.9 |
) |
Asset impairments, restructuring, and other special charges,
net of tax |
|
|
|
|
|
|
979.7 |
|
Other, net |
|
|
(83.3 |
) |
|
|
33.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
NET CASH PROVIDED BY OPERATING ACTIVITIES |
|
|
942.2 |
|
|
|
1,478.9 |
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Net purchases of property and equipment |
|
|
(392.1 |
) |
|
|
(619.9 |
) |
Net change in short-term investments |
|
|
103.9 |
|
|
|
1,337.8 |
|
Purchase of noncurrent investments |
|
|
(1,003.2 |
) |
|
|
(218.1 |
) |
Proceeds from sales and maturities of noncurrent investments |
|
|
906.2 |
|
|
|
270.8 |
|
Other, net |
|
|
126.9 |
|
|
|
(145.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES |
|
|
(258.3 |
) |
|
|
625.5 |
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Dividends paid |
|
|
(864.6 |
) |
|
|
(821.2 |
) |
Purchases of common stock |
|
|
(122.1 |
) |
|
|
|
|
Repayment of long-term debt |
|
|
(100.1 |
) |
|
|
(94.0 |
) |
Issuances of common stock under stock plans |
|
|
13.9 |
|
|
|
34.9 |
|
Net change in short-term borrowings |
|
|
4.9 |
|
|
|
(1,791.9 |
) |
Other, net |
|
|
.2 |
|
|
|
7.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
NET CASH USED IN FINANCING ACTIVITIES |
|
|
(1,067.8 |
) |
|
|
(2,664.3 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
46.9 |
|
|
|
(163.0 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
|
(337.0 |
) |
|
|
(722.9 |
) |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at January 1 |
|
|
3,006.7 |
|
|
|
5,365.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS AT JUNE 30 |
|
$ |
2,669.7 |
|
|
$ |
4,642.4 |
|
|
|
|
See Notes to Consolidated Condensed Financial Statements.
4
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Eli Lilly and Company and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
Net income (loss) |
|
$ |
822.0 |
|
|
$ |
(252.0 |
) |
|
$ |
1,656.8 |
|
|
$ |
484.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss)1 |
|
|
170.5 |
|
|
|
(345.9 |
) |
|
|
300.7 |
|
|
|
(517.0 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss) |
|
$ |
992.5 |
|
|
$ |
(597.9 |
) |
|
$ |
1,957.5 |
|
|
$ |
(32.4 |
) |
|
|
|
|
|
|
1 |
|
The significant components of other comprehensive income (loss) were gains of $172.5
million and $223.3 million from foreign currency translation adjustments for the three months and
six months ended June 30, 2006, respectively, compared to losses from foreign currency translation
adjustments of $247.9 million and $386.4 million for the three months and six months ended June 30,
2005, respectively. Gains from cash flow hedges were $11.5 million and $78.3 million for the three
months and six months ended June 30, 2006, respectively, compared to losses of $104.7 million and
$114.3 million from cash flow hedges for the three months and six months ended June 30, 2005,
respectively. |
|
|
|
See Notes to Consolidated Condensed Financial Statements. |
5
SEGMENT INFORMATION
We operate in one significant business segment pharmaceutical products. Operations of our animal
health business segment are not material and share many of the same economic and operating
characteristics as our pharmaceutical products. Therefore, they are included with pharmaceutical
products for purposes of segment reporting. Our business segments are distinguished by the
ultimate end user of the product: humans or animals. Performance is evaluated based on profit or
loss from operations before income taxes. Income before income taxes for the animal health
business for the second quarter of 2006 and 2005 was $40.9 million and $47.3 million, respectively,
and $75.1 million and $87.3 million for the six months ended June 30, 2006 and 2005, respectively.
SALES BY PRODUCT CATEGORY
Worldwide sales by product category for the three months and six months ended June 30, 2005 and
2004 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
Net sales to unaffiliated customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neurosciences |
|
$ |
1,686.2 |
|
|
$ |
1,547.4 |
|
|
$ |
3,193.3 |
|
|
$ |
2,975.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Endocrinology |
|
|
1,231.2 |
|
|
|
1,141.8 |
|
|
|
2,459.8 |
|
|
|
2,286.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology |
|
|
496.7 |
|
|
|
454.4 |
|
|
|
965.8 |
|
|
|
855.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal health |
|
|
201.0 |
|
|
|
201.0 |
|
|
|
399.3 |
|
|
|
396.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular |
|
|
127.5 |
|
|
|
155.7 |
|
|
|
270.6 |
|
|
|
323.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anti-infectives |
|
|
69.6 |
|
|
|
112.8 |
|
|
|
157.5 |
|
|
|
222.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other pharmaceuticals |
|
|
54.7 |
|
|
|
54.6 |
|
|
|
135.3 |
|
|
|
105.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
3,866.9 |
|
|
$ |
3,667.7 |
|
|
$ |
7,581.6 |
|
|
$ |
7,165.1 |
|
|
|
|
6
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
BASIS OF PRESENTATION
We have prepared the accompanying unaudited consolidated condensed financial statements in
accordance with the requirements of Form 10-Q and, therefore, they do not include all information
and footnotes necessary for a fair presentation of financial position, results of operations, and
cash flows in conformity with accounting principles generally accepted in the United States (GAAP).
In our opinion, the financial statements reflect all adjustments (including those that are normal
and recurring) that are necessary for a fair presentation of the results of operations for the
periods shown. In preparing financial statements in conformity with GAAP, we must make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and
related disclosures at the date of the financial statements and during the reporting period.
Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with
our consolidated financial statements and accompanying notes included in our Annual Report on Form
10-K for the year ended December 31, 2005.
CONTINGENCIES
We are engaged in the following patent litigation matters brought pursuant to procedures set out in
the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984):
|
|
|
Dr. Reddys Laboratories, Ltd. (Reddy), Teva Pharmaceuticals, and Zenith Goldline
Pharmaceuticals, Inc., which was subsequently acquired by Teva Pharmaceuticals (together,
Teva), each submitted abbreviated new drug applications (ANDAs) seeking permission to
market generic versions of Zyprexa® prior to the expiration of our relevant U.S. patent
(expiring in 2011) and alleging that this patent was invalid or not enforceable. We filed
lawsuits against these companies in the U.S. District Court for the Southern District of
Indiana, seeking a ruling that the patent is valid, enforceable and being infringed. The
district court ruled in our favor on all counts on April 14, 2005. We are now awaiting a
decision by the Court of Appeals for the Federal Circuit, which on April 6, 2006, heard
Reddys and Tevas respective appeals of this ruling. We are confident Reddys and Tevas
claims are without merit and we expect to prevail. However, it is not possible to predict
or determine the outcome of this litigation, and accordingly, we can provide no assurance
that we will prevail on appeal. An unfavorable outcome would have a material adverse
impact on our consolidated results of operations, liquidity, and financial position. |
|
|
|
|
Barr Laboratories, Inc. (Barr), submitted an ANDA in 2002 seeking permission to market a
generic version of Evistaâ prior to the expiration of our relevant U.S. patents
(expiring in 2012-2017) and alleging that these patents are invalid, not enforceable, or
not infringed. In November 2002, we filed a lawsuit against Barr in the U.S. District Court
for the Southern District of Indiana, seeking a ruling that these patents are valid,
enforceable, and being infringed by Barr. Teva has also submitted an ANDA seeking
permission to market a generic version of Evista. In June 2006, we filed a lawsuit against
Teva in the U.S. District Court for the Southern District of Indiana, seeking a ruling that
our relevant U.S. patents (expiring in 2012-2014) are valid, enforceable, and being
infringed by Teva. No trial date has been set in either case. We believe Barrs and
Tevas claims are without merit and we expect to prevail. However, it is not possible to
predict or determine the outcome of this litigation, and accordingly, we can provide no
assurance that we will prevail. An unfavorable outcome could have a material adverse
impact on our consolidated results of operations, liquidity, and financial position. |
|
|
|
|
Sicor Pharmaceuticals, Inc. (Sicor), a subsidiary of Teva, submitted ANDAs in November
2005 seeking permission to market generic versions of Gemzar® prior to the expiration of
our relevant U.S. patents (expiring in 2010 and 2013), and alleging that these patents are
invalid. In February, we filed a lawsuit against Sicor in the U.S. District Court for the
Southern District of Indiana, seeking a ruling that these patents are valid and are being
infringed by Sicor. In response to our lawsuit, Sicor filed a declaratory judgment action
in the U.S. District Court for the Central District of California. No trial date has been
set in either matter. We believe Sicors claims are without merit and we expect to
prevail. However, it is not possible to predict or determine the outcome of this
litigation, and accordingly, we can provide no assurance that we will prevail. An
unfavorable outcome could have a material adverse impact on our consolidated results of
operations. |
In March 2004, the office of the U.S. Attorney for the Eastern District of Pennsylvania advised us
that it has commenced a civil investigation related to our U.S. marketing and promotional
practices, including our communications with physicians and remuneration of physician consultants
and advisors, with respect to Zyprexa, Prozac®, and Prozac Weekly. In October 2005, the U.S.
Attorneys office advised that it is also conducting an inquiry regarding certain rebate agreements
we entered into with a pharmacy benefit manager covering Axid®, Evista, Humalogâ,
Humulinâ, Prozac, and Zyprexa. The inquiry includes a review of Lillys Medicaid best price
reporting related
to the product sales covered by the rebate agreements. We are cooperating with the U.S. Attorney in
these investigations, including providing a broad range of documents
and information relating to the
7
investigations. In June 2005, we received a subpoena from the office of the Attorney General,
Medicaid Fraud Control Unit, of the State of Florida, seeking production of documents relating to
sales of Zyprexa and our marketing and promotional practices with respect to Zyprexa. It is
possible that other Lilly products could become subject to investigation and that the outcome of
these matters could include criminal charges and fines, penalties, or other monetary or nonmonetary
remedies. We cannot predict or determine the outcome of these matters or reasonably estimate the
amount or range of amounts of any fines or penalties that might result from an adverse outcome. It
is possible, however, that an adverse outcome could have a material adverse impact on our
consolidated results of operations, liquidity, and financial position. We have implemented and
continue to review and enhance a broadly based compliance program that includes comprehensive
compliance-related activities designed to ensure that our marketing and promotional practices,
physician communications, remuneration of health care professionals, managed care arrangements, and
Medicaid best price reporting comply with applicable laws and regulations.
We have been named as a defendant in a large number of Zyprexa product liability lawsuits in the
United States and have been notified of many other claims of individuals who have not filed suit.
The lawsuits and unfiled claims (together the claims) allege a variety of injuries from the use
of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high
blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically
accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the
claims also allege that we improperly promoted the drug. Almost all of the federal lawsuits are
part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the
Federal District Court for the Eastern District of New York (MDL No. 1596). The MDL includes three
lawsuits requesting certification of class actions on behalf of those who allegedly suffered
injuries from the administration of Zyprexa. We have entered into agreements with various
plaintiffs counsel halting the running of the statutes of limitation (tolling agreements) with
respect to a number of claimants who do not have lawsuits on file.
Since June 2005, we have entered into agreements with various claimants attorneys involved in U.S.
Zyprexa product liability litigation to settle a majority of the claims. The agreements cover
approximately 10,500 claimants, including a large number of previously filed lawsuits (including
the three purported class actions mentioned above), tolled claims, and other informally asserted
claims. The settlements are being overseen and distributed by court-approved claims
administrators. The agreements are subject to certain conditions, including obtaining full
releases from a specified number of claimants.
The U.S. Zyprexa product liability claims not subject to these agreements include approximately
1,400 lawsuits in the U.S. covering approximately 7,600 claimants, and approximately 850 tolled
claims. In addition, we have been served with a lawsuit seeking class certification in which the
members of the purported class are seeking refunds and medical monitoring. Finally, in early 2005,
we were served with four lawsuits seeking class action status in Canada on behalf of patients who
took Zyprexa. One of these four lawsuits has been certified for residents of Quebec. The
allegations in the Canadian actions are similar to those in the litigation pending in the United
States. We are prepared to continue our vigorous defense of Zyprexa in all remaining cases.
In December 2004, we were served with two lawsuits brought in state court in Louisiana on behalf of
the Louisiana Department of Health and Hospitals, alleging that Zyprexa caused or contributed to
diabetes or high blood-glucose levels, and that we improperly promoted the drug. These cases have
been removed to federal court and are now part of the MDL proceedings in the Eastern District of
New York. In these actions, the Department of Health and Hospitals seeks to recover the costs it
paid for Zyprexa through Medicaid and other drug-benefit programs, as well as the costs the
department alleges it has incurred and will incur to treat Zyprexa-related illnesses. In 2006, we
were served with similar lawsuits filed by the states of Alaska, West Virginia, and Mississippi in
the courts of the respective states.
In 2005, two lawsuits were filed in the Eastern District of New York purporting to be nationwide
class actions on behalf of all consumers and third-party payors, excluding governmental entities,
which have made or will make payments for their members or insured patients being prescribed
Zyprexa. These actions have now been consolidated into a single lawsuit, which is brought under
certain state consumer protection statutes, the federal civil RICO statute, and common law
theories, seeking a refund of the cost of Zyprexa, treble damages, punitive damages, and attorneys
fees. Four additional lawsuits were filed in 2006: two in the Eastern District of New York, one
in the Southern District of Indiana, and one in Indiana state court, all on similar grounds. As
with the product liability suits, these lawsuits allege that we inadequately tested for and warned
about side effects of Zyprexa and improperly promoted the drug.
We have insurance coverage for a portion of our Zyprexa product liability claims exposure. The
third-party insurance carriers have raised defenses to their liability under the policies and are
seeking to rescind the policies. The dispute is now the subject of litigation in the federal court
in Indianapolis against certain of the carriers and in arbitration in Bermuda against other
carriers. While we believe our position is meritorious, there can be no assurance that we will
prevail.
In addition, we have been named as a defendant in numerous other product liability lawsuits
involving primarily diethylstilbestrol (DES) and thimerosal.
8
With respect to the product liability claims currently asserted against us, we have accrued for our
estimated exposures to the extent they are both probable and estimable based on the information
available to us. In addition, we have accrued for certain product liability claims incurred but
not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these
expenses based primarily on historical claims experience and data regarding product usage. Legal
defense costs expected to be incurred in connection with significant product liability loss
contingencies are accrued when probable and reasonably estimable. A portion of the costs
associated with defending and disposing of these suits is covered by insurance. We record
receivables for insurance-related recoveries when it is probable they will be realized. These
receivables are classified as a reduction of the litigation charges on the statement of income. We
estimate insurance recoverables based on existing deductibles, coverage limits, our assessment of
any defenses to coverage that might be raised by the carriers, and the existing and projected
future level of insolvencies among the insurance carriers.
In the second quarter of 2005, we recorded a net pre-tax charge of $1.07 billion for product
liability matters. The $1.07 billion net charge takes into account our estimated recoveries from
our insurance coverage related to these matters. The charge covers the following:
|
|
|
The cost of the Zyprexa settlements described above; and, |
|
|
|
|
Reserves for product liability exposures and defense costs regarding currently known and
expected claims to the extent we can formulate a reasonable estimate of the probable number
and cost of the claims. A substantial majority of these exposures and costs relate to
current and expected Zyprexa claims not included in the settlements. We have estimated
these charges based primarily on historical claims experience, data regarding product
usage, and our historical product liability defense cost experience. |
During 2005, $700.0 million was paid in connection with Zyprexa settlements, while the cash related
to other reserves for product liability exposures and defense costs is expected to be paid out over
the next several years, including 2006. The timing of our insurance recoveries is uncertain.
We cannot predict with certainty the additional number of lawsuits and claims that may be asserted.
In addition, although we believe it is probable, there can be no assurance that the Zyprexa
settlements described above will be concluded. The ultimate resolution of Zyprexa product
liability and related litigation could have a material adverse impact on our consolidated results
of operations, liquidity, and financial position.
Because of the nature of pharmaceutical products, it is possible that we could become subject to
large numbers of product liability claims for other products in the future. We have experienced
difficulties in obtaining product liability insurance due to a very restrictive insurance market,
and therefore will be largely self-insured for future product liability losses. In addition, as
noted above, there is no assurance that we will be able to fully collect from our insurance
carriers on past claims.
In June 2002, we were sued by Ariad Pharmaceuticals, Inc., the Massachusetts Institute of
Technology, the Whitehead Institute for Biomedical Research and the President and Fellows of
Harvard College in the U.S. District Court for the District of Massachusetts alleging that sales of
two of our products, Xigris® and Evista, were inducing the infringement of a patent related to the
discovery of a natural cell signaling phenomenon in the human body and seeking royalties on past
and future sales of these products. We believe that these allegations are without legal merit and
that we will ultimately prevail on these issues. In June 2005, the United States Patent and
Trademark Office commenced a re-examination of the patent in order to consider certain issues
raised by us relating to the validity of the patent. A jury trial commenced in Boston on April 10,
2006 on the patent validity and infringement issues. On May 4, 2006, the jury issued an initial
decision in the case that Xigris and Evista sales infringe the patent. The jury awarded the
plaintiffs approximately $65 million in damages, calculated by applying a 2.3 percent royalty to
all U.S. sales of Xigris and Evista from the date of issuance of the patent through the date of
trial. We will seek to have the jury verdict overturned by the trial court judge, and if
unsuccessful, will appeal the decision to the Court of Appeals for the Federal Circuit. In
addition, a separate bench trial with the U.S. District Court of Massachusetts is scheduled to
begin on August 7, 2006, and will be held on our contention that the patent is unenforceable and
will also consider the patents improper coverage of natural processes.
Also, under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly
known as Superfund, we have been designated as one of several potentially responsible parties with
respect to fewer than 10 sites. Under Superfund, each responsible party may be jointly and
severally liable for the entire amount of the cleanup. We also continue remediation of certain of
our own sites. We have accrued for estimated Superfund cleanup costs, remediation, and certain
other environmental matters. This takes into account, as applicable, available information
regarding site conditions, potential cleanup methods, estimated costs, and the extent to which
other parties can be expected to contribute to payment of those costs. We have reached a settlement
with our liability insurance carriers providing for coverage for certain environmental liabilities.
The litigation accruals and environmental liabilities and the related estimated insurance
recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our
consolidated balance sheets.
9
While it is not possible to predict or determine the outcome of the patent, product liability, or
other legal actions brought against us or the ultimate cost of environmental matters, we believe
that, except as noted above, the resolution of all such matters will not have a material adverse
effect on our consolidated financial position or liquidity, but could possibly be material to the
consolidated results of operations in any one accounting period.
EARNINGS PER SHARE
Unless otherwise noted in the footnotes, all per-share amounts are presented on a diluted basis,
that is, based on the weighted-average number of outstanding common shares plus the effect of all
potentially dilutive common shares (primarily unexercised stock options). Loss per-share amounts
are presented based on a basic calculation; that is, based on the weighted-average number of
outstanding common shares.
STOCK-BASED COMPENSATION
We adopted Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment
(SFAS 123R), effective January 1, 2005. SFAS 123R requires the recognition of the fair value of
stock-based compensation in net income. Stock-based compensation primarily consists of stock
options and performance awards. We recognized pretax stock-based compensation cost in the amount
of $91.1 million and $100.0 million in the second quarter of 2006 and 2005, respectively. In the
first half of 2006 and 2005, we recognized stock-based compensation expense of $191.3 million and
$208.2 million, respectively.
As of June 30, 2006, the total remaining unrecognized compensation cost related to nonvested stock
options and performance awards amounted to $183.4 million and $102.4 million, respectively, which
will be amortized over the weighted-average remaining requisite service periods, which are
approximately 19 months and 6 months, respectively.
Under our policy, all stock option awards are approved prior to the date of grant and the exercise
price is the average of the high and low market price on the date of grant. The Compensation
Committee of the Board of Directors approves the value of the award and the date of grant. All
option awards for senior management are approved by the Compensation Committee. Options that are
awarded as part of annual total compensation for senior management and other employees are made on
specific grant dates scheduled in advance. With respect to option awards given to new hires, our
policy requires approval of such awards prior to the grant date, and the options are granted on a
pre-determined monthly date immediately following the date of hire.
RETIREMENT BENEFITS
Net pension and retiree health benefit expense included the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Defined Benefit Pension Plans |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
Components of net periodic benefit cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost |
|
$ |
68.8 |
|
|
$ |
74.3 |
|
|
$ |
138.1 |
|
|
$ |
154.4 |
|
Interest cost |
|
|
81.5 |
|
|
|
74.2 |
|
|
|
162.2 |
|
|
|
149.0 |
|
Expected return on plan assets |
|
|
(120.8 |
) |
|
|
(112.9 |
) |
|
|
(240.2 |
) |
|
|
(223.0 |
) |
Amortization of prior service cost |
|
|
1.5 |
|
|
|
1.9 |
|
|
|
2.9 |
|
|
|
3.9 |
|
Recognized actuarial loss |
|
|
32.8 |
|
|
|
26.0 |
|
|
|
63.1 |
|
|
|
52.2 |
|
|
|
|
Net periodic benefit cost |
|
$ |
63.8 |
|
|
$ |
63.5 |
|
|
$ |
126.1 |
|
|
$ |
136.5 |
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retiree Health Benefit Plans |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
Components of net periodic benefit cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost |
|
$ |
16.3 |
|
|
$ |
14.7 |
|
|
$ |
36.0 |
|
|
$ |
29.4 |
|
Interest cost |
|
|
24.4 |
|
|
|
20.0 |
|
|
|
48.8 |
|
|
|
40.1 |
|
Expected return on plan assets |
|
|
(23.0 |
) |
|
|
(18.7 |
) |
|
|
(45.0 |
) |
|
|
(35.7 |
) |
Amortization of prior service cost |
|
|
(3.9 |
) |
|
|
(4.0 |
) |
|
|
(7.7 |
) |
|
|
(8.0 |
) |
Recognized actuarial loss |
|
|
28.8 |
|
|
|
21.5 |
|
|
|
53.9 |
|
|
|
43.1 |
|
|
|
|
Net periodic benefit cost |
|
$ |
42.6 |
|
|
$ |
33.5 |
|
|
$ |
86.0 |
|
|
$ |
68.9 |
|
|
|
|
In 2006, we expect to contribute approximately $30 million to our defined benefit pension plans
to satisfy minimum funding requirements for the year. In addition, we expect to contribute
approximately $140 million of additional discretionary funding in 2006 to our defined benefit
plans. We also expect to contribute approximately $90 million of discretionary funding to our
postretirement health benefit plans during 2006. As of June 30, 2006, $42.6 million of
contributions have been made to these plans and the majority of our remaining expected
contributions were made in early July 2006.
OTHER INCOME NET
Other income net, was comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
|
(Dollars in millions) |
Interest expense |
|
$ |
65.8 |
|
|
$ |
12.0 |
|
|
$ |
130.8 |
|
|
$ |
36.6 |
|
Interest income |
|
|
(68.4 |
) |
|
|
(46.3 |
) |
|
|
(128.1 |
) |
|
|
(92.3 |
) |
Joint venture (income) loss |
|
|
(22.5 |
) |
|
|
.5 |
|
|
|
(42.3 |
) |
|
|
13.1 |
|
Other |
|
|
(21.8 |
) |
|
|
(11.6 |
) |
|
|
(39.5 |
) |
|
|
(101.4 |
) |
|
|
|
|
|
$ |
(46.9 |
) |
|
$ |
(45.4 |
) |
|
$ |
(79.1 |
) |
|
$ |
(144.0 |
) |
|
|
|
The joint venture (income) loss represents our share of the Lilly ICOS LLC joint venture results of
operations, net of income taxes.
SHAREHOLDERS EQUITY
As of June 30, 2006, we have purchased $2.58 billion of our previously announced $3.0 billion share
repurchase program. During the six months ended June 30, 2006, we acquired 2.1 million shares
pursuant to this program. We do not expect any share repurchases for the remainder of 2006.
IMPLEMENTATION OF NEW FINANCIAL ACCOUNTING PRONOUNCEMENTS
In the fourth quarter of 2005, we adopted Financial Accounting Standards Board (FASB)
Interpretation (FIN) 47, Accounting for Conditional Asset Retirement Obligations, an
interpretation of FASB Statement No. 143. FIN 47 requires us to record the fair value of a
liability for conditional asset retirement obligations in the period in which it is incurred,
which is adjusted to its present value each subsequent period. In addition, we are required to
capitalize a corresponding amount by increasing the carrying amount of the related long-lived
asset, which is depreciated over the useful life of the related long-lived asset. The adoption of
FIN 47 on December 31, 2005, resulted in a cumulative effect of a change in accounting principle
of $22.0 million, net of income taxes of $11.8 million.
In July 2006, the FASB issued FIN 48, Accounting for Uncertainty in Income Taxes, an
interpretation of FASB Statement No. 109. FIN 48 prescribes a recognition threshold and
measurement attribute for the financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return. The Interpretation is effective for fiscal years
beginning after December 15, 2006; therefore, we will be required to adopt this Interpretation in
the first quarter of 2007. We are currently evaluating FIN 48 and have not yet determined the
impact, if any, the adoption of this Interpretation will have on our consolidated financial
position or results of operations.
11
POTENTIAL ASSET IMPAIRMENTS, RESTRUCTURING, AND OTHER SPECIAL CHARGES
As part of our ongoing efforts to maximize performance and efficiencies, including the streamlining
of manufacturing operations and research and development activities, we are discussing the future
of three European facilities, including proposals to close the sites, which include two research
and development sites and one manufacturing site. Any site closures
would be subject to consultations
with employee representatives at the affected sites. Following these consultations, which could
take several months, final recommendations will be made to the Lilly Board of Directors, which must
approve any action. No final decisions have been made about the future of the sites at this time.
However, if the proposals proceed, the majority of the 900 employees plus contractors at those
sites would be laid off and we would attempt to dispose of the facilities. As a consequence, we
would incur severance and impairment charges that would likely be significant.
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
OPERATING RESULTS
Executive Overview
I. Financial Results
The second-quarter and first-half 2006 net income was $822.0 million, or $.76 per share, and $1.66
billion, or $1.53 per share, respectively. Second-quarter 2005 net loss and loss per share was
$252.0 million and $.23. However, net income was $484.6 million, or $.44 per share for the first
half of 2005. The net loss and loss per share in the second quarter of 2005 was the result of a
product liability litigation charge of $1.07 billion (pretax) in the quarter. In addition to this
product liability charge, changes in earnings between the periods were driven primarily by
increased sales and decreased cost of sales for the second quarter and first half of 2006, offset
partially by decreased total other income in the first half of 2006.
II. Recent Product and Late-Stage Pipeline Developments
|
|
|
Gemzar was approved in the U.S. for the treatment of recurrent ovarian cancer in
combination with carboplatin. |
|
|
|
|
We submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
for review of ruboxistaurin mesylate (proposed brand name ArxxantTM) as an oral
medication to reduce the risk of vision loss associated with diabetic retinopathy. The FDA
subsequently informed us that our Arxxant application is fileable and will be given a
priority review. We also submitted Arxxant for approval in Europe for the same indication. |
|
|
|
|
We submitted a supplemental NDA to the FDA for Cymbaltaâ for the treatment of
generalized anxiety disorder. We are also conducting Phase III studies on Cymbalta for the
treatment of fibromyalgia, a chronic, often debilitating pain disorder. |
|
|
|
|
We initiated a Phase III clinical trial to study enzastaurin as a maintenance therapy to
prevent relapse in patients with diffuse large B-cell lymphoma. Enzastaurin, a targeted
oral agent, is also being studied in Phase III trials for the treatment of relapsed
glioblastoma multiforme, an aggressive and malignant form of brain cancer. |
III. Legal, Regulatory, and Other Matters
Certain generic manufacturers have challenged our U.S. compound patent for Zyprexa and are
seeking permission to market generic versions of Zyprexa prior to its patent expiration in 2011.
On April 14, 2005, the U.S. District Court in Indianapolis ruled in our favor on all counts,
upholding our patents. The decision has been appealed.
We have reached agreements with claimants attorneys involved in certain U.S. Zyprexa product
liability litigation to settle a majority of the claims against us relating to the medication.
A large number of claims remain. As a result of our product liability exposures, the
substantial majority of which were related to Zyprexa, we recorded a net pretax charge of $1.07
billion in the second quarter of 2005.
In March 2004, we were notified by the U.S. Attorneys office for the Eastern District of
Pennsylvania that it has commenced a civil investigation relating to our U.S. sales, marketing,
and promotional practices.
We announced that we are discussing the future of three European facilities, including proposals to
close the sites. Any site closures would be subject to consultations with employee representatives
at the affected sites and final approval by the Board of Directors. No final decisions have been
made at this time. If the sites are closed, the majority of the 900 employees would be laid off
and we would record charges that would likely be significant.
12
In the United States, implementation of the Medicare Prescription Drug, Improvement and
Modernization Act of 2003 (MMA), which provides a prescription drug benefit under the Medicare
program, took effect January 1, 2006. While it is difficult to predict the business impact of
this legislation, we currently anticipate a modest short-term increase in sales. However, in
the long term there is additional risk of increased pricing pressures. While the MMA prohibits
the Secretary of Health and Human Services (HHS) from directly negotiating prescription drug
prices with manufacturers, we expect continued challenges to that prohibition over the next
several years. Also, the MMA retains the authority of the Secretary of HHS to prohibit the
importation of prescription drugs, but we expect Congress to consider several measures that
could remove that authority and allow for the importation of products into the U.S. regardless
of their safety or cost. If adopted, such legislation would likely have a negative effect on
our U.S. sales. We believe there is some chance that the new and expanded prescription drug
coverage for seniors under the MMA will alleviate the perceived need for a federal importation
scheme. Additionally, notwithstanding the federal law prohibiting drug importation,
approximately a dozen states have implemented importation schemes for their citizens, usually
involving a website that links patients to selected Canadian pharmacies. One state has such a
program for its state employees.
As a result of the passage of the MMA, aged and disabled patients jointly eligible for Medicare
and Medicaid began receiving their prescription drug benefits through the Medicare program,
instead of Medicaid, on January 1, 2006. This may relieve some state budget pressures but is
unlikely to result in reduced pricing pressures at the state level. A majority of states have
implemented supplemental rebates and restricted formularies in their Medicaid programs, and
these programs are expected to continue in the post-MMA environment. Moreover, under the 2005
federal Deficit Reduction Act, states will have greater flexibility to impose new cost-sharing
requirements on Medicaid beneficiaries for non-preferred prescription drugs that will result in
certain beneficiaries bearing more of the cost. Several states also are attempting to extend
discounted Medicaid prices to non-Medicaid patients. As a result, we expect pressures on
pharmaceutical pricing to continue.
As it relates to the new Medicare program, we announced in the second quarter of 2006 that we have
temporarily extended our U.S. patient assistance program, LillyAnswers. The temporary extension of
LillyAnswers allows patients who are not enrolled in Medicare Part D access to the LillyAnswers
program until December 31, 2006. We also temporarily extended LillyAnswers for patients who have
enrolled in a Medicare Part D plan and need assistance for Zyprexa and Forteoâ. We have
asked the U.S. Department of Health and Human Services Office of the Inspector General (OIG) for an
opinion on our proposal for an Outside Part D patient assistance program (i.e., the
LillyMedicareAnswers program) which would provide assistance primarily for Zyprexa and Forteo,
beyond the end of this year to patients enrolled in a Medicare Part D plan. We currently
anticipate that the specific LillyAnswers program extension involving Zyprexa and Forteo for
patients enrolled in a Medicare Part D plan will continue to be available until a decision is
rendered by the OIG on our proposal. In order to participate in either the temporary extension as
described above or the new proposed LillyMedicareAnswers program, certain eligibility and
certification requirements must be met.
International operations also are generally subject to extensive price and market regulations,
and there are many proposals for additional cost-containment measures, including proposals that
would directly or indirectly impose additional price controls or reduce the value of our
intellectual property protection.
Sales
Second-quarter and first-half 2006 sales growth of 5 and 6 percent, respectively, was driven
primarily by sales growth of Cymbalta, Forteo, Alimtaâ, and Byettaâ. The growth
comparisons also benefited from an estimated $160 million of wholesaler destocking in the first six
months of 2005 as a result of restructuring our arrangements with our U.S. wholesalers in the first
quarter of 2005. Sales in the U.S. increased by $158.4 million, or 8 percent, and $349.0 million,
or 9 percent, for the second quarter and first half of 2006, respectively, compared with the same
periods of 2005. Sales outside the U.S. increased $40.8 million, or 2 percent, and $67.4 million,
or 2 percent, for the second quarter and first half of 2006, respectively. For the second quarter,
sales volume and selling prices each increased sales by 3 percent, while exchange rates decreased
sales by 1 percent. For the first six months of 2006, worldwide sales volume and selling prices
increased 5 percent and 3 percent, respectively, while exchange rates decreased 2 percent.
13
The following tables summarize our net sales activity for the three- and six-month periods ended
June 30, 2006 and 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
Three Months Ended |
|
June 30, |
|
Percent |
|
|
June 30, 2006 |
|
2005 |
|
Change |
Product |
|
U.S.1 |
|
Outside U.S. |
|
Total |
|
Total |
|
from 2005 |
|
|
|
|
|
|
(Dollars in millions) |
|
|
|
|
|
|
|
|
Zyprexa |
|
$ |
542.9 |
|
|
$ |
572.1 |
|
|
$ |
1,115.0 |
|
|
$ |
1,096.8 |
|
|
|
2 |
|
Gemzar |
|
|
150.0 |
|
|
|
193.5 |
|
|
|
343.5 |
|
|
|
343.0 |
|
|
|
0 |
|
Humalog |
|
|
196.6 |
|
|
|
123.9 |
|
|
|
320.5 |
|
|
|
296.2 |
|
|
|
8 |
|
Cymbalta |
|
|
269.9 |
|
|
|
40.5 |
|
|
|
310.4 |
|
|
|
161.4 |
|
|
|
92 |
|
Evista |
|
|
175.0 |
|
|
|
100.5 |
|
|
|
275.5 |
|
|
|
261.6 |
|
|
|
5 |
|
Humulin |
|
|
79.9 |
|
|
|
139.9 |
|
|
|
219.8 |
|
|
|
249.8 |
|
|
|
(12 |
) |
Animal health products |
|
|
92.7 |
|
|
|
108.3 |
|
|
|
201.0 |
|
|
|
201.0 |
|
|
|
0 |
|
Alimta |
|
|
87.7 |
|
|
|
65.3 |
|
|
|
153.0 |
|
|
|
111.2 |
|
|
|
38 |
|
Forteo |
|
|
101.0 |
|
|
|
45.1 |
|
|
|
146.1 |
|
|
|
101.9 |
|
|
|
43 |
|
Strattera |
|
|
125.9 |
|
|
|
18.2 |
|
|
|
144.1 |
|
|
|
123.5 |
|
|
|
17 |
|
Humatrope |
|
|
52.0 |
|
|
|
56.0 |
|
|
|
108.0 |
|
|
|
108.9 |
|
|
|
(1 |
) |
Actos |
|
|
50.9 |
|
|
|
41.7 |
|
|
|
92.6 |
|
|
|
105.0 |
|
|
|
(12 |
) |
Fluoxetine products |
|
|
39.5 |
|
|
|
40.5 |
|
|
|
80.0 |
|
|
|
114.2 |
|
|
|
(30 |
) |
ReoPro |
|
|
28.3 |
|
|
|
44.0 |
|
|
|
72.3 |
|
|
|
77.7 |
|
|
|
(7 |
) |
Anti-infectives |
|
|
3.5 |
|
|
|
66.1 |
|
|
|
69.6 |
|
|
|
112.8 |
|
|
|
(38 |
) |
Byetta |
|
|
52.1 |
|
|
|
|
|
|
|
52.1 |
|
|
|
3.3 |
|
|
NM |
Cialis2 |
|
|
0.8 |
|
|
|
49.7 |
|
|
|
50.5 |
|
|
|
45.1 |
|
|
|
12 |
|
Xigris |
|
|
25.1 |
|
|
|
23.3 |
|
|
|
48.4 |
|
|
|
57.7 |
|
|
|
(16 |
) |
Other pharmaceutical
products |
|
|
23.9 |
|
|
|
40.6 |
|
|
|
64.5 |
|
|
|
96.6 |
|
|
|
(33 |
) |
|
|
|
|
|
Total net sales |
|
$ |
2,097.7 |
|
|
$ |
1,769.2 |
|
|
$ |
3,866.9 |
|
|
$ |
3,667.7 |
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
|
Six Months Ended |
|
June 30, |
|
Percent |
|
|
June 30, 2006 |
|
2005 |
|
Change |
Product |
|
U.S.1 |
|
Outside U.S. |
|
Total |
|
Total |
|
from 2005 |
|
|
|
|
|
|
(Dollars in millions) |
|
|
|
|
|
|
|
|
Zyprexa |
|
$ |
1,036.8 |
|
|
$ |
1,085.6 |
|
|
$ |
2,122.4 |
|
|
$ |
2,135.0 |
|
|
|
(1 |
) |
Gemzar |
|
|
299.7 |
|
|
|
382.6 |
|
|
|
682.3 |
|
|
|
647.6 |
|
|
|
5 |
|
Humalog |
|
|
385.2 |
|
|
|
239.8 |
|
|
|
625.0 |
|
|
|
582.4 |
|
|
|
7 |
|
Cymbalta |
|
|
475.8 |
|
|
|
67.9 |
|
|
|
543.7 |
|
|
|
268.2 |
|
|
|
103 |
|
Evista |
|
|
324.1 |
|
|
|
192.9 |
|
|
|
517.0 |
|
|
|
510.5 |
|
|
|
1 |
|
Humulin |
|
|
168.1 |
|
|
|
270.2 |
|
|
|
438.3 |
|
|
|
506.7 |
|
|
|
(13 |
) |
Animal health products |
|
|
176.7 |
|
|
|
222.6 |
|
|
|
399.3 |
|
|
|
396.5 |
|
|
|
1 |
|
Strattera |
|
|
261.2 |
|
|
|
35.2 |
|
|
|
296.4 |
|
|
|
243.2 |
|
|
|
22 |
|
Alimta |
|
|
165.6 |
|
|
|
117.6 |
|
|
|
283.2 |
|
|
|
205.1 |
|
|
|
38 |
|
Actos |
|
|
202.3 |
|
|
|
79.4 |
|
|
|
281.7 |
|
|
|
273.6 |
|
|
|
3 |
|
Forteo |
|
|
188.2 |
|
|
|
84.9 |
|
|
|
273.1 |
|
|
|
168.7 |
|
|
|
62 |
|
Humatrope |
|
|
100.2 |
|
|
|
104.4 |
|
|
|
204.6 |
|
|
|
213.4 |
|
|
|
(4 |
) |
Fluoxetine products |
|
|
75.6 |
|
|
|
81.8 |
|
|
|
157.4 |
|
|
|
226.7 |
|
|
|
(31 |
) |
Anti-infectives |
|
|
24.3 |
|
|
|
133.2 |
|
|
|
157.5 |
|
|
|
222.0 |
|
|
|
(29 |
) |
ReoPro |
|
|
57.8 |
|
|
|
88.6 |
|
|
|
146.4 |
|
|
|
154.4 |
|
|
|
(5 |
) |
Cialis2 |
|
|
1.9 |
|
|
|
104.3 |
|
|
|
106.2 |
|
|
|
84.0 |
|
|
|
26 |
|
Xigris |
|
|
52.9 |
|
|
|
45.7 |
|
|
|
98.6 |
|
|
|
117.3 |
|
|
|
(16 |
) |
Byetta |
|
|
88.0 |
|
|
|
|
|
|
|
88.0 |
|
|
|
3.3 |
|
|
NM |
Other pharmaceutical
products |
|
|
48.6 |
|
|
|
111.9 |
|
|
|
160.5 |
|
|
|
206.5 |
|
|
|
(22 |
) |
|
|
|
|
|
Total net sales |
|
$ |
4,133.0 |
|
|
$ |
3,448.6 |
|
|
$ |
7,581.6 |
|
|
$ |
7,165.1 |
|
|
|
6 |
|
|
|
|
|
|
NM Not Meaningful
1 U.S. sales include sales in Puerto Rico.
2 Cialisâ had worldwide second-quarter and first-half 2006 sales of $233.2 million
and $456.1 million, respectively, representing increases of 22 and 34 percent, respectively,
compared with the same periods of 2005. The sales shown in the tables above represent results in
the territories in which we market Cialis exclusively. The remaining sales relate to the
joint-venture territories of Lilly ICOS LLC (North America, excluding Puerto Rico, and Europe).
Our share of the joint-venture territory sales, net of expenses, is
reported in other income net in
our consolidated condensed statements of income.
14
Product Highlights
Zyprexa sales in the U.S. decreased 1 percent and 3 percent in the second quarter and first half of
2006, respectively, compared with the same periods of 2005. This decrease was a result of a
decline in the underlying demand, offset in part by higher net effective selling prices. The
increase in net effective selling prices was partially due to the transition of certain low income
patients from Medicaid to Medicare. Despite the decline in demand as compared to prior year, we
are seeing improving U.S. prescription trends. Specifically, Zyprexas U.S. prescriptions have
held steady during the first six months of 2006. Sales of Zyprexa outside the U.S. increased by 5
percent in the second quarter and 2 percent in the first half of 2006, due to increased demand,
offset partially by the unfavorable impact of foreign exchange rates.
Diabetes care products, composed primarily of Humalog, Humulin, Actosâ, and Byetta, had
worldwide net sales of $701.7 million and $1.47 billion in the second quarter and first half of
2006, respectively, an increase of 5 percent compared with the same periods last year. Diabetes
care revenues in the U.S. increased 6 percent and 9 percent, to $392.6 million and $868.1 million
for the second quarter and first half of 2006, led by sales of Byetta. Diabetes care revenues
outside the U.S. increased 4 percent and remained flat, to $309.1 million and $597.0 million in the
second quarter and first half of 2006, respectively. Humalog sales in the U.S. increased 8 percent
during both the second quarter and first half of 2006, due to higher prices, which were partially
offset by a decline in demand during the second quarter. Humalog sales outside of the U.S.
increased 8 percent and 7 percent during the second quarter and first half of 2006, respectively,
due primarily to increased demand, offset in part by the unfavorable impact of foreign exchange
rates. Humulin sales decreased 22 percent and 19 percent in the U.S. in the second quarter and
first half of 2006, respectively, driven primarily by the decline in demand due to continued
competitive pressures. Humulin sales outside of the U.S. decreased 5 percent and 10 percent during
the second quarter and first half of 2006, respectively, due to decreased demand and the
unfavorable impact of foreign exchange rates. Actos revenues, the majority of which represent
service revenues from a copromotion agreement in the U.S. with Takeda Pharmaceuticals North America
(Takeda), decreased 29 percent and 3 percent in the second quarter and first half of 2006 in the
U.S. Actos is manufactured by Takeda Chemical Industries, Ltd., and sold in the U.S. by Takeda.
As previously disclosed, since our share of revenue from the agreement with Takeda will vary from
quarter to quarter based on contract terms, Actos revenue will not necessarily track with product
sales. As a result, it is difficult to make quarterly comparisons for Actos revenue. Our U.S.
marketing rights with respect to Actos expire in September 2006; however, we will continue
receiving royalties from Takeda. As a result, our U.S. revenues from Actos will decline in 2006
and each subsequent year. Our arrangement in the U.S. ceases after October 2009, although our
arrangement outside the U.S. continues. Sales of Byetta, a first-in-class treatment for type 2
diabetes that we market with Amylin Pharmaceuticals and launched in the U.S. in June 2005, were
$98.6 million and $166.6 million for the second quarter and first half of 2006, respectively. We
report as revenue our 50 percent share of Byettas gross margin and our sales of Byettas pen
delivery devices to Amylin.
Gemzar sales decreased 3 percent and increased 6 percent in the U.S. for the second quarter and
first half of 2006, respectively, reflecting decreased demand due to competitive pressures in the
second quarter. Gemzar sales outside the U.S. increased 3 and 4 percent for the second quarter and
first half of 2006, respectively, due to increased demand, offset partially by the unfavorable
impact of foreign exchange rates.
U.S. sales of Cymbalta, a treatment of major depressive disorder and diabetic peripheral
neuropathic pain, increased 79 percent and 88 percent in the second quarter and first half of 2006,
respectively, reflecting increased demand. Also during the second quarter, Cymbaltas U.S. market
share growth accelerated. Specifically, Cymbaltas U.S. share of new prescriptions increased 0.96
percentage points in the second quarter, compared with a 0.35 percentage point gain
in the first quarter of 2006, per IMS Health, National Prescription Audit Plus 7, July 2006.
Sales outside the U.S. reflect international launches in key markets, including Germany, the U.K.,
Italy, Spain, Mexico, and Brazil.
Evista sales in the U.S. increased 7 percent and 1 percent in the second quarter and first half of
2006, respectively, due to price increases in both periods, offset partially by decreased demand in
the first half of 2006. Evista sales outside the U.S. increased 2
15
percent in the second quarter
and first half of 2006 compared with the same periods of 2005, due to increased demand, offset
partially by lower prices and the unfavorable impact of foreign exchange rates.
Stratteraâ, a treatment for attention-deficit hyperactivity disorder (ADHD) in children,
adolescents, and adults, generated increases in U.S. sales of 13 percent and 17 percent for the
second quarter and first half of 2006, compared with the same periods in 2005. The sales increases
for both periods were primarily due to reductions in the U.S. wholesaler inventory levels in 2005
and higher prices, offset partially by a decline in demand in the U.S.
Alimta, a treatment for malignant pleural mesothelioma and second-line treatment of non-small-cell
lung cancer, generated increased U.S. sales of 26 percent and 25 percent in the second quarter and
first half of 2006, respectively; while sales outside the U.S. increased 56 percent and 63 percent
for the same periods in 2005.
Forteo, a treatment for severe osteoporosis, increased 43 percent and 67 percent in the U.S. in the
second quarter and first half of 2006, respectively; while sales outside the U.S. increased 45
percent and 52 percent for the same periods. Increased sales in the U.S. were due in part to
greater access to medical coverage through the MMA program.
Cialis sales in the second quarter and first half of 2006 were comprised of $50.5 million and
$106.2 million of sales in our territories, respectively, which are reported in our net sales, and
$182.7 million and $349.9 million of sales in the joint-venture territories. Within the
joint-venture territories, the U.S. sales of Cialis were $93.8 million and $176.3 million in the
second quarter and first half of 2006, respectively, compared with $71.1 million and $113.9 million
in the same periods of 2005. Cialis sales in our territories are reported in revenue, while our 50
percent share of the joint-venture territory sales, net of expenses, is reported in other income
net. Cialis sales growth reflects both gains in market share and growth of the erectile
dysfunction market during the second quarter and first half of 2006.
Gross Margin, Costs, and Expenses
For the second quarter of 2006, gross margins increased 1.5 percentage points, to 77.7 percent of
net sales, compared with the second quarter of 2005. For the first half of 2006, gross margins
increased 2.1 percentage points, to 78.0 percent of net sales, compared with the first half of
2005. This increase was primarily due to favorable product mix and the favorable impact of foreign
exchange rates, partially offset by higher manufacturing-related costs.
Operating expenses (the aggregate of research and development and marketing and administrative
expenses) increased 5 percent for both the second quarter and first half of 2006. Investment in
research and development increased 2 percent, to $774.8 million, and 3 percent, to $1.52 billion,
for the second quarter and first half of 2006, respectively, due primarily to increased discovery
research expenses. Marketing and administrative expenses increased 8 percent, to $1.24 billion,
and 6 percent, to $2.38 billion, for the second quarter and first half of 2006, respectively,
primarily due to increased marketing expenses in support of newer products, offset partially by the
impact of foreign exchange rates.
Other income net consists of interest expense, interest income, the after-tax operating results
of the Lilly ICOS joint venture, and all other income and expense items.
|
|
|
Second-quarter and first-half 2006 interest expense increased $53.8 million, to $65.8
million, and $94.2 million to $130.8 million, respectively, as a result of higher interest
rates and less capitalized interest due to the completion in late 2005 of certain
manufacturing facilities. |
|
|
|
|
Interest income increased $22.1 million, to $68.4 million and $35.8 million to $128.1
million for the second quarter and first half of 2006, respectively, due to higher interest
rates. |
|
|
|
|
The Lilly ICOS joint-venture income was $22.5 million in the second quarter of 2006,
compared with a loss of $.5 million in the second quarter of 2005. For the first half of
2006, income was $42.3 million, compared with a loss of $13.1 million in the first half of
2005. The increase in both periods was due to increased Cialis sales and decreased selling
and marketing expenses. |
|
|
|
|
Net other income and expense items increased $10.2 million to $21.8 million for
second-quarter 2006 and decreased $61.9 million to $39.5 million for first-half 2006. The
first-half decrease is largely a result of less income from business development
transactions. |
We incurred a tax expense of $218.5 million and $440.4 million, for the second quarter and first
half of 2006, respectively, representing an effective tax rate of 21 percent in both periods.
Comparisons to prior year are not meaningful due to the net loss before income taxes experienced in
the second quarter of 2005.
16
FINANCIAL CONDITION
As of June 30, 2006, cash, cash equivalents, and short-term investments totaled $4.59 billion
compared with $5.04 billion at December 31, 2005. Cash flow from operations of $942.2 million
during the first six months of 2006 was more than offset by dividends paid of $864.6 million, net
capital expenditures of $392.1 million, and repurchases of common stock of $122.1 million.
Total debt at June 30, 2006, was $6.32 billion, a decrease of $181.6 million from December 31,
2005. Our current debt ratings from Standard & Poors and Moodys remain at AA and Aa3,
respectively.
We believe that cash generated from operations, along with available cash and cash equivalents,
will be sufficient to fund our operating needs, including debt service, capital expenditures,
dividends, and taxes in 2006. We believe that amounts available through our existing commercial
paper program should be adequate to fund maturities of short-term borrowings, if necessary. We
currently have $1.23 billion of unused committed bank credit facilities, $1.20 billion of which
backs our commercial paper program. We currently expect to repay approximately $1.5 billion of
debt during 2006, using available cash. Various risks and uncertainties, including those
discussed in the Financial Expectations for 2006 section, may affect our operating results and
cash generated from operations.
LEGAL AND REGULATORY MATTERS
We are engaged in the following patent litigation matters brought pursuant to procedures set out in
the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984):
|
|
|
Dr. Reddys Laboratories, Ltd. (Reddy), Teva Pharmaceuticals, and Zenith Goldline
Pharmaceuticals, Inc., which was subsequently acquired by Teva Pharmaceuticals (together,
Teva), each submitted abbreviated new drug applications (ANDAs) seeking permission to
market generic versions of Zyprexa prior to the expiration of our relevant U.S. patent
(expiring in 2011) and alleging that this patent was invalid or not enforceable. We filed
lawsuits against these companies in the U.S. District Court for the Southern District of
Indiana, seeking a ruling that the patent is valid, enforceable and being infringed. The
district court ruled in our favor on all counts on April 14, 2005. We are now awaiting a
decision by the Court of Appeals for the Federal Circuit, which on April 6, 2006, heard
Reddys and Tevas respective appeals of this ruling. We are confident Reddys and Tevas
claims are without merit and we expect to prevail. However, it is not possible to predict
or determine the outcome of this litigation, and accordingly, we can provide no assurance
that we will prevail on appeal. An unfavorable outcome would have a material adverse
impact on our consolidated results of operations, liquidity, and financial position. |
|
|
|
|
Barr Laboratories, Inc. (Barr), submitted an ANDA in 2002 seeking permission to market a
generic version of Evista prior to the expiration of our relevant U.S. patents (expiring in
2012-2017) and alleging that these patents are invalid, not enforceable, or not infringed.
In November 2002, we filed a lawsuit against Barr in the U.S. District Court for the
Southern District of Indiana, seeking a ruling that these patents are valid, enforceable,
and being infringed by Barr. Teva has also submitted an ANDA seeking permission to market
a generic version of Evista. In June 2006, we filed a lawsuit against Teva in the U.S.
District Court for the Southern District of Indiana, seeking a ruling that our relevant
U.S. patents (expiring in 2012-2014) are valid, enforceable, and being infringed by Teva.
No trial date has been set in either case. We believe Barrs and Tevas claims are without
merit and we expect to prevail. However, it is not possible to predict or determine the
outcome of this litigation, and accordingly, we can provide no assurance that we will
prevail. An unfavorable outcome could have a material adverse impact on our consolidated
results of operations, liquidity, and financial position. |
|
|
|
|
Sicor Pharmaceuticals, Inc. (Sicor), a subsidiary of Teva, submitted ANDAs in November
2005 seeking permission to market generic versions of Gemzar prior to the expiration of our
relevant U.S. patents (expiring in 2010 and 2013), and alleging that these patents are invalid. In February, we filed a
lawsuit against Sicor in the U.S. District Court for the Southern District of Indiana,
seeking a ruling that these patents are valid and are being infringed by Sicor. In response
to our lawsuit, Sicor filed a declaratory judgment action in the U.S. District Court for the
Central District of California. No trial date has been set in either matter. We believe
Sicors claims are without merit and we expect to prevail. However, it is not possible to
predict or determine the outcome of this litigation, and accordingly, we can provide no
assurance that we will prevail. An unfavorable outcome could have a material adverse impact
on our consolidated results of operations. |
In March 2004, the office of the U.S. Attorney for the Eastern District of Pennsylvania advised us
that it has commenced a civil investigation related to our U.S. marketing and promotional
practices, including our communications with physicians and remuneration of physician consultants
and advisors, with respect to Zyprexa, Prozac, and Prozac Weekly. In October 2005, the U.S.
Attorneys office advised that it is also conducting an inquiry regarding certain rebate agreements
we entered into with a pharmacy benefit manager covering Axid, Evista, Humalog, Humulin, Prozac,
and Zyprexa. The inquiry includes a review of Lillys Medicaid best price reporting related to the
product sales covered by the rebate agreements. We are cooperating with the U.S.
17
Attorney
in these
investigations, including providing a broad range of documents and information relating to the
investigations. In June 2005, we received a subpoena from the office of the Attorney General,
Medicaid Fraud Control Unit, of the State of Florida, seeking production of documents relating to
sales of Zyprexa and our marketing and promotional practices with respect to Zyprexa. It is
possible that other Lilly products could become subject to investigation and that the outcome of
these matters could include criminal charges and fines, penalties, or other monetary or nonmonetary
remedies. We cannot predict or determine the outcome of these matters or reasonably estimate the
amount or range of amounts of any fines or penalties that might result from an adverse outcome. It
is possible, however, that an adverse outcome could have a material adverse impact on our
consolidated results of operations, liquidity, and financial position. We have implemented and
continue to review and enhance a broadly based compliance program that includes comprehensive
compliance-related activities designed to ensure that our marketing and promotional practices,
physician communications, remuneration of health care professionals, managed care arrangements, and
Medicaid best price reporting comply with applicable laws and regulations.
We have been named as a defendant in a large number of Zyprexa product liability lawsuits in the
United States and have been notified of many other claims of individuals who have not filed suit.
The lawsuits and unfiled claims (together the claims) allege a variety of injuries from the use
of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high
blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically
accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the
claims also allege that we improperly promoted the drug. Almost all of the federal lawsuits are
part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the
Federal District Court for the Eastern District of New York (MDL No. 1596). The MDL includes three
lawsuits requesting certification of class actions on behalf of those who allegedly suffered
injuries from the administration of Zyprexa. We have entered into agreements with various
plaintiffs counsel halting the running of the statutes of limitation (tolling agreements) with
respect to a number of claimants who do not have lawsuits on file.
Since June 2005, we have entered into agreements with various claimants attorneys involved in U.S.
Zyprexa product liability litigation to settle a majority of the claims. The agreements cover
approximately 10,500 claimants, including a large number of previously filed lawsuits (including
the three purported class actions mentioned above), tolled claims, and other informally asserted
claims. The settlements are being overseen and distributed by court-approved claims
administrators. The agreements are subject to certain conditions, including obtaining full
releases from a specified number of claimants.
The U.S. Zyprexa product liability claims not subject to these agreements include approximately
1,400 lawsuits in the U.S. covering approximately 7,600 claimants, and approximately 850 tolled
claims. In addition, we have been served with a lawsuit seeking class certification in which the
members of the purported class are seeking refunds and medical monitoring. Finally, in early 2005,
we were served with four lawsuits seeking class action status in Canada on behalf of patients who
took Zyprexa. One of these four lawsuits has been certified for residents of Quebec. The
allegations in the Canadian actions are similar to those in the litigation pending in the United
States. We are prepared to continue our vigorous defense of Zyprexa in all remaining cases.
In December 2004, we were served with two lawsuits brought in state court in Louisiana on behalf of
the Louisiana Department of Health and Hospitals, alleging that Zyprexa caused or contributed to
diabetes or high blood-glucose levels, and that we improperly promoted the drug. These cases have
been removed to federal court and are now part of the MDL proceedings in the Eastern District of
New York. In these actions, the Department of Health and Hospitals
seeks to recover the costs it paid for Zyprexa through Medicaid and other drug-benefit programs, as
well as the costs the department alleges it has incurred and will incur to treat Zyprexa-related
illnesses. In 2006, we were served with similar lawsuits filed by the states of Alaska, West
Virginia, and Mississippi in the courts of the respective states.
In 2005, two lawsuits were filed in the Eastern District of New York purporting to be nationwide
class actions on behalf of all consumers and third-party payors, excluding governmental entities,
which have made or will make payments for their members or insured patients being prescribed
Zyprexa. These actions have now been consolidated into a single lawsuit, which is brought under
certain state consumer protection statutes, the federal civil RICO statute, and common law
theories, seeking a refund of the cost of Zyprexa, treble damages, punitive damages, and attorneys
fees. Four additional lawsuits were filed in 2006: two in the Eastern District of New York, one
in the Southern District of Indiana, and one in Indiana state court, all on similar grounds. As
with the product liability suits, these lawsuits allege that we inadequately tested for and warned
about side effects of Zyprexa and improperly promoted the drug.
We have insurance coverage for a portion of our Zyprexa product liability claims exposure. The
third-party insurance carriers have raised defenses to their liability under the policies and are
seeking to rescind the policies. The dispute is now the subject of litigation in the federal court
in Indianapolis against certain of the carriers and in arbitration in Bermuda against other
carriers. While we believe our position is meritorious, there can be no assurance that we will
prevail.
In addition, we have been named as a defendant in numerous other product liability lawsuits
involving primarily diethylstilbestrol (DES) and thimerosal.
18
With respect to the product liability claims currently asserted against us, we have accrued for our
estimated exposures to the extent they are both probable and estimable based on the information
available to us. In addition, we have accrued for certain product liability claims incurred but
not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these
expenses based primarily on historical claims experience and data regarding product usage. Legal
defense costs expected to be incurred in connection with significant product liability loss
contingencies are accrued when probable and reasonably estimable. A portion of the costs
associated with defending and disposing of these suits is covered by insurance. We record
receivables for insurance-related recoveries when it is probable they will be realized. These
receivables are classified as a reduction of the litigation charges on the statement of income. We
estimate insurance recoverables based on existing deductibles, coverage limits, our assessment of
any defenses to coverage that might be raised by the carriers, and the existing and projected
future level of insolvencies among the insurance carriers.
In the second quarter of 2005, we recorded a net pre-tax charge of $1.07 billion for product
liability matters. The $1.07 billion net charge takes into account our estimated recoveries from
our insurance coverage related to these matters. The charge covers the following:
|
|
|
The cost of the Zyprexa settlements described above; and, |
|
|
|
|
Reserves for product liability exposures and defense costs regarding currently known and
expected claims to the extent we can formulate a reasonable estimate of the probable number
and cost of the claims. A substantial majority of these exposures and costs relate to
current and expected Zyprexa claims not included in the settlements. We have estimated
these charges based primarily on historical claims experience, data regarding product
usage, and our historical product liability defense cost experience. |
During 2005, $700.0 million was paid in connection with Zyprexa settlements, while the cash related
to other reserves for product liability exposures and defense costs is expected to be paid out over
the next several years, including 2006. The timing of our insurance recoveries is uncertain.
We cannot predict with certainty the additional number of lawsuits and claims that may be asserted.
In addition, although we believe it is probable, there can be no assurance that the Zyprexa
settlements described above will be concluded. The ultimate resolution of Zyprexa product
liability and related litigation could have a material adverse impact on our consolidated results
of operations, liquidity, and financial position.
Because of the nature of pharmaceutical products, it is possible that we could become subject to
large numbers of product liability claims for other products in the future. We have experienced
difficulties in obtaining product liability insurance due to a very restrictive insurance market,
and therefore will be largely self-insured for future product
liability losses. In addition, as noted above, there is no assurance that we will be able to fully
collect from our insurance carriers on past claims.
In June 2002, we were sued by Ariad Pharmaceuticals, Inc., the Massachusetts Institute of
Technology, the Whitehead Institute for Biomedical Research and the President and Fellows of
Harvard College in the U.S. District Court for the District of Massachusetts alleging that sales of
two of our products, Xigris and Evista, were inducing the infringement of a patent related to the
discovery of a natural cell signaling phenomenon in the human body and seeking royalties on past
and future sales of these products. We believe that these allegations are without legal merit and
that we will ultimately prevail on these issues. In June 2005, the United States Patent and
Trademark Office commenced a re-examination of the patent in order to consider certain issues
raised by us relating to the validity of the patent. A jury trial commenced in Boston on April 10,
2006 on the patent validity and infringement issues. On May 4, 2006, the jury issued an initial
decision in the case that Xigris and Evista sales infringe the patent. The jury awarded the
plaintiffs approximately $65 million in damages, calculated by applying a 2.3 percent royalty to
all U.S. sales of Xigris and Evista from the date of issuance of the patent through the date of
trial. We will seek to have the jury verdict overturned by the trial court judge, and if
unsuccessful, will appeal the decision to the Court of Appeals for the Federal Circuit. In
addition, a separate bench trial with the U.S. District Court of Massachusetts is scheduled to
begin on August 7, 2006, and will be held on our contention that the patent is unenforceable and
will also consider the patents improper coverage of natural processes.
Also, under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly
known as Superfund, we have been designated as one of several potentially responsible parties with
respect to fewer than 10 sites. Under Superfund, each responsible party may be jointly and
severally liable for the entire amount of the cleanup. We also continue remediation of certain of
our own sites. We have accrued for estimated Superfund cleanup costs, remediation, and certain
other environmental matters. This takes into account, as applicable, available information
regarding site conditions, potential cleanup methods, estimated costs, and the extent to which
other parties can be expected to contribute to payment of those costs. We have reached a
settlement with our liability insurance carriers providing for coverage for certain environmental
liabilities.
19
The litigation accruals and environmental liabilities and the related estimated insurance
recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our
consolidated balance sheets.
While it is not possible to predict or determine the outcome of the patent, product liability, or
other legal actions brought against us or the ultimate cost of environmental matters, we believe
that, except as noted above, the resolution of all such matters will not have a material adverse
effect on our consolidated financial position or liquidity, but could possibly be material to the
consolidated results of operations in any one accounting period.
FINANCIAL EXPECTATIONS FOR 2006
We expect third-quarter earnings per share of $.77 to $.79, representing 5 percent to 8 percent
growth compared with third-quarter 2005 earnings per share of $.73. For the full year of 2006, we
expect earnings per share to be in the range of $3.10 to $3.20. This guidance excludes future
material unusual items, such as any charges related to the three potential European site closures
discussed previously. We expect full-year 2006 sales to grow at approximately the low end of our
previous guidance of 7 percent to 9 percent. In addition, we expect gross margins as a percent of
sales to improve modestly compared with 2005, operating expenses to grow in the mid-single digits
in the aggregate, and other income net, to contribute approximately $175 million to $275 million.
Excluding the tax associated with the potential charges discussed above, we also anticipate the
effective tax rate to be approximately 21 percent. In terms of cash flow, we expect capital
expenditures to be flat at about $1.4 billion in 2006.
We caution investors that any forward-looking statements or projections made by us, including those
above, are based on managements belief at the time they are made. However, they are subject to
risks and uncertainties. Actual results could differ materially and will depend on, among other
things, the continuing growth of our currently marketed products; developments with competitive
products; the timing and scope of regulatory approvals and the success of our new product launches;
asset impairments, restructurings, and acquisitions of compounds under development resulting in
acquired in-process research and development charges; foreign exchange rates; wholesaler inventory
changes; the outcome of the Zyprexa patent appeal; other regulatory developments, government
investigations, patent disputes and litigation; and the impact of governmental actions regarding
pricing, importation, and reimbursement for pharmaceuticals. Other factors that may affect our
operations and prospects are discussed in Item 1A of our 2005 Form 10-K, Risk Factors. We
undertake no duty to update these forward-looking statements.
AVAILABLE INFORMATION ON OUR WEBSITE
We make available through our company website, free of charge, our company filings with the
Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically
file them with, or furnish them to, the SEC. The reports we make available include annual reports
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements,
registration statements, and any amendments to those documents.
The website link to our SEC filings is http://investor.lilly.com/edgar.cfm.
Item 4. Controls and Procedures
(a) |
|
Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations,
management of a reporting company, with the participation of the principal executive officer
and principal financial officer, must periodically evaluate the companys disclosure controls
and procedures, which are defined generally as controls and other procedures of a reporting
company designed to ensure that information required to be disclosed by the reporting company
in its periodic reports filed with the commission (such as this Form 10-Q) is recorded,
processed, summarized, and reported on a timely basis. |
|
|
|
Our management, with the participation of Sidney Taurel, chairman and chief executive officer,
and Derica W. Rice, senior vice president and chief financial officer, evaluated our disclosure
controls and procedures as of June 30, 2006, and concluded that they are effective. |
(b) |
|
Changes in Internal Controls. During the second quarter of 2006, there were no changes in
our internal control over financial reporting that materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. |
20
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
See Part I, Item 2, Managements Discussion and Analysis, Legal and Regulatory Matters, for
information on various legal proceedings, including but not limited to:
|
|
|
The U.S. patent litigation involving Zyprexa, Evista, and Gemzar |
|
|
|
|
The civil investigation by the U.S. Attorney for the Eastern District of Pennsylvania
relating to our U.S. sales, marketing, and promotional practices |
|
|
|
|
The Zyprexa product liability and related litigation, including claims brought on behalf
of healthcare payors |
|
|
|
|
The legal proceedings we have filed against several of our product liability insurance
carriers with respect to our coverage for the Zyprexa product liability claims |
That information is incorporated into this Item by reference.
Other Product Liability Litigation
We refer to Part I, Item 3, of our Form 10-K annual report for 2005 for the discussion of product
liability litigation involving diethylstilbestrol (DES) and vaccines containing the preservative
thimerosal. In the DES litigation, we have been named as a defendant in approximately 80 suits
involving approximately 170 claimants. In the thimerosal litigation, we have been named as a
defendant in approximately 360 suits with approximately 975 claimants.
While it is not possible to predict or determine the outcome of the patent, product liability, or
other legal actions brought against us or the ultimate cost of environmental matters, we believe
that, except as noted above, the resolution of all such matters will not have a material adverse
effect on our consolidated financial position or liquidity but could possibly be material to the
consolidated results of operations in any one accounting period.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table summarizes the activity related to repurchases of our equity securities during
the three-month period ended June 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number of |
|
|
|
|
|
|
|
|
|
|
|
|
Shares Purchased as |
|
Approximate Dollar |
|
|
|
|
|
|
|
|
|
|
Part of Publicly |
|
Value of Shares that May |
|
|
Total Number of |
|
Average Price Paid |
|
Announced Plans or |
|
Yet Be Purchased Under |
|
|
Shares Purchased |
|
per Share |
|
Programs |
|
the Plans or Programs |
Period |
|
(a) |
|
(b) |
|
(c) |
|
(d) |
|
|
(in thousands) |
|
|
|
|
|
(in thousands) |
|
(Dollars in millions) |
April 2006 |
|
|
3 |
|
|
$ |
53.49 |
|
|
|
|
|
|
$ |
419.2 |
|
May 2006 |
|
|
15 |
|
|
|
52.52 |
|
|
|
|
|
|
|
419.2 |
|
June 2006 |
|
|
10 |
|
|
|
54.02 |
|
|
|
|
|
|
|
419.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The amounts presented in columns (a) and (b) above include purchases of common stock related to
employee stock option exercises. The amounts presented in columns (c) and (d) in the above table
represent activity related only to our $3.0 billion share repurchase program announced in March
2000. As of June 30, 2006, we have purchased $2.58 billion related to this program. During the
second quarter of 2006, no shares were repurchased pursuant to this program and we do not expect to
purchase any shares under this program during the remainder of 2006.
21
Item 6. Exhibits
The following documents are filed as exhibits to this Report:
|
|
|
|
|
|
|
EXHIBIT 10.
|
|
Master Settlement Agreement regarding Zyprexa product liability claims, filed
here in its entirety to include its Exhibit A, which was inadvertently omitted from our
Form 10-Q for the quarter ended September 30, 2005 |
|
|
|
|
|
|
|
EXHIBIT 11.
|
|
Statement re: Computation of Earnings (Loss) per Share |
|
|
|
|
|
|
|
EXHIBIT 12.
|
|
Statement re: Computation of Ratio of Earnings to Fixed Charges |
|
|
|
|
|
|
|
EXHIBIT 31.1
|
|
Rule 13a-14(a) Certification of Sidney Taurel, Chairman of the Board and Chief
Executive Officer |
|
|
|
|
|
|
|
EXHIBIT 31.2
|
|
Rule 13a-14(a) Certification of Derica W. Rice, Senior Vice President and Chief
Financial Officer |
|
|
|
|
|
|
|
EXHIBIT 32.
|
|
Section 1350 Certification |
22
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this Report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
ELI LILLY AND COMPANY
(Registrant)
|
|
Date August 1, 2006 |
/s/ James B. Lootens
|
|
|
James B. Lootens |
|
|
Secretary and Deputy General Counsel |
|
|
|
|
|
|
|
|
|
|
Date August 1, 2006 |
/s/ Arnold C. Hanish
|
|
|
Arnold C. Hanish |
|
|
Executive Director, Finance, and
Chief Accounting Officer |
|
|
23
INDEX TO EXHIBITS
The following documents are filed as a part of this Report:
|
|
|
|
|
|
|
Exhibit |
|
|
|
|
|
EXHIBIT 10.
|
|
Master Settlement Agreement regarding Zyprexa product liability
claims, filed here in its entirety to include its Exhibit A, which was
inadvertently omitted from our Form 10-Q for the quarter ended September 30,
2005 |
|
|
|
|
|
|
|
EXHIBIT 11.
|
|
Statement re: Computation of Earnings (Loss) per Share |
|
|
|
|
|
|
|
EXHIBIT 12.
|
|
Statement re: Computation of Ratio of Earnings to Fixed Charges |
|
|
|
|
|
|
|
EXHIBIT 31.1
|
|
Rule 13a-14(a) Certification of Sidney Taurel, Chairman of the Board
and Chief Executive Officer |
|
|
|
|
|
|
|
EXHIBIT 31.2
|
|
Rule 13a-14(a) Certification of Derica W. Rice, Senior Vice President
and Chief Financial Officer |
|
|
|
|
|
|
|
EXHIBIT 32.
|
|
Section 1350 Certification |
24